H. Lee Moffitt Cancer Center & Research Institute
Welcome,         Profile    Billing    Logout  
 348 Trials 
581 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weber, Jeffrey S
NCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Hourglass Jan 2023 - Dec 2023 : Results for stage I-III MCC that has been completely removed by surgery
Active, not recruiting
3
280
US
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
12/25
12/25
NCT03999749: A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Active, not recruiting
2
71
US
Ipilimumab, Nivolumab, Tocilizumab
NYU Langone Health
Melanoma
07/23
01/25
NCT05428007: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting
2
69
US
Sarilumab, REGN88, Ipilimumab Injection, BMS-734016, MDX010, MDX-CTLA4, Nivolumab/Relatlimab, BMS-986213
NYU Langone Health
Melanoma, Unresectable Melanoma
06/25
12/25
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
AIM-NIVO, NCT03816345: Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting
1
300
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
08/26
08/26
Alsina, Melissa
NCT04151667: Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
33
US
Daratumumab Injection, Darzalex, Dexamethasone Oral, Decadron, Lenalidomide Pill, Revlimid, Bortezomib Injection, Velcade
H. Lee Moffitt Cancer Center and Research Institute, Janssen Scientific Affairs, LLC
Multiple Myeloma
11/23
11/24
NCT06660355: Ruxolitinib Vs Prednisone As First-line Therapy for CGVHD Needing Systemic Therapy

Not yet recruiting
2
120
US
Ruxolitinib, Prednisone
H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation
Chronic Graft-versus-host Disease (cGVHD)
11/28
11/28
NCT03605927: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Completed
1
45
US
BMS-986004, Anti-CD40L Domain Antibody, Sirolimus, Standard of Care, SIR, Tacrolimus, TAC
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Graft-versus-host-disease, GVHD, GVHD, Acute
09/23
09/23
NCT05015426: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Active, not recruiting
1
20
US
Gamma Delta T-Cell Infusion
H. Lee Moffitt Cancer Center and Research Institute, Florida Department of Health
Acute Myeloid Leukemia
09/25
09/26
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

Recruiting
N/A
69
US
Autologous Stem Cell Transplant, Immunomodulatory Agent, Proteasome Inhibitor
H. Lee Moffitt Cancer Center and Research Institute, Adaptive Biotechnologies
Multiple Myeloma
02/25
02/25
NCT05763563: Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Recruiting
N/A
20
US
Resistance Training, Aerobic Exercise, Optional Aerobic Exercise Procedure, Optional In-Person Exercise Sessions
H. Lee Moffitt Cancer Center and Research Institute, Cancer and Aging Research Group
Lymphoma, Leukemia, Myeloma
06/25
06/25
Sullivan, Daniel M
NCT02007382: Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Recruiting
1
68
US, Canada
Trametinib, GSK1120212
University Health Network, Toronto, National Cancer Institute (NCI)
Solid Tumors, Hepatic Dysfunction
06/15
12/15
NCT00258570: Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
N/A
2000
US
University of Pittsburgh
Pulmonary Fibrosis
07/35
07/35
NCT00258583: Dorothy P. and Richard P. Simmons Center for ILD Research Registry

Recruiting
N/A
5000
US
University of Pittsburgh
Lung Diseases, Interstitial
07/35
07/35
NCT00373841: Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
N/A
500
US
University of Pittsburgh
Idiopathic Pulmonary Fibrosis
07/30
07/30
Antonia, Scott J
TOP2101, NCT05144529: A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Recruiting
2
38
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Evolocumab, Repatha
Scott Antonia
Lung Cancer Metastatic
06/25
06/27
NCT05553834: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Recruiting
2
60
US
Alirocumab and Cemiplimab
Duke University, Regeneron Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
01/27
01/29
Nieder, Michael
NCT03057054: Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

Active, not recruiting
3
173
Canada, US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Lactobacillus plantarum strain 299, DSM 6595, LACTOBACILLUS PLANTARUM 299, Lactobacillus plantarum strain 299v, DSM 9843, LACTIPLANTIBACILLUS PLANTARUM 299V, Lp 299v, Placebo Administration
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Leukemia, Lymphoma
06/22
06/26
NCT05127174: Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Active, not recruiting
1/2
12
US
Fedratinib Pill, Inrebic
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Myeloproliferative Neoplasm
08/25
08/25
NCT03605927: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Completed
1
45
US
BMS-986004, Anti-CD40L Domain Antibody, Sirolimus, Standard of Care, SIR, Tacrolimus, TAC
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Graft-versus-host-disease, GVHD, GVHD, Acute
09/23
09/23
NCT05015426: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Active, not recruiting
1
20
US
Gamma Delta T-Cell Infusion
H. Lee Moffitt Cancer Center and Research Institute, Florida Department of Health
Acute Myeloid Leukemia
09/25
09/26
Munster, Pamela N
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
BRCA-P, NCT04711109 / 2017-002505-35: Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Recruiting
3
300
US
Denosumab, Placebo, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Austrian Breast & Colorectal Cancer Study Group (ABCSG)
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
07/27
12/33
NCT04190056: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Terminated
2
1
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Tamoxifen, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
University of California, San Francisco, Merck Sharp & Dohme LLC
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
06/23
06/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
12/24
04/25
ATLAS-101, NCT04503265: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Active, not recruiting
1/2
122
US
AMXI-5001:Dose Escalation Phase I, Phase I, Dose Escalation, AMXI-5001:Dose Expansion Phase II, Phase II, Dose Expansion
AtlasMedx, Incorporated
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
01/25
01/25
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
DF1001-001, NCT04143711: Study of DF1001 in Patients With Advanced Solid Tumors

Recruiting
1/2
378
Europe, US
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics
Solid Tumor, Adult
10/26
12/26
Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed
1
17
US, RoW
Bicalutamide implant
Alessa Therapeutics Inc.
Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
05/23
05/23
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Active, not recruiting
1
208
US, RoW
BB-1701
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Locally Advanced/Metastatic HER2 Positive Solid Tumors
08/24
12/24
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
NCT04678648: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Recruiting
1
134
US
RSC-1255 Dose Escalation, Phase 1a, Dose Escalation, RSC-1255 Dose Expansion, Phase 1b, Dose Expansion
RasCal Therapeutics, Inc.
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
07/25
09/25
NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
More
Active, not recruiting
1
90
US
PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib
Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Metastatic Solid Tumors
01/24
12/24
NCT06177171: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Recruiting
1
18
US
Olaparib, LYNPARZA, ASTX727, INQOVI, C-DEC
Pamela Munster, National Cancer Institute (NCI)
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
01/26
11/26
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
01/30
01/30
NCT05277051: First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Recruiting
1
141
Europe, Canada, Japan, US, RoW
GSK4381562, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
GlaxoSmithKline
Neoplasms
09/28
09/28
NCT05694715: Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting
1
24
US
Niraparib, Zejula, Small molecule inhibitor, Irinotecan, Camptosar, Irinotecan hydrochloride, CPT-11
University of California, San Francisco, GlaxoSmithKline
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
01/28
01/28
NCT05058846: Pilot Study of Pancreatic Cancer Screening

Recruiting
N/A
250
US
Biospecimen Collection, Biological Sample Collection, Magnetic Resonance Cholangiopancreatography, MRCP, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Endoscopic ultrasound, EUS, Questionnaires, Surveys
University of California, San Francisco
Pancreatic Carcinoma
01/32
01/32
Haura, Eric B
NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Terminated
1
9
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Lurbinectedin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Jazz Pharmaceuticals
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
03/23
03/23
NCT04774952: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
108
US
RMC-5552
Revolution Medicines, Inc.
Solid Tumors
03/24
03/24
Strosberg, Jonathan
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
ACTION-1, NCT05477576: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymic Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymic Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymic Neuroendocrine Neoplasm
08/23
05/25
NCT01253161: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Completed
2
29
US
Pasireotide Long Acting Release (LAR), SOM 230
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals, RECORDATI GROUP
Neuroendocrine Tumors, Carcinoid Tumors
10/21
03/23
NCT03290079: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Completed
2
20
US
Pembrolizumab, Keytruda®, Lenvatinib, Lenvima®
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
01/23
05/24
NCT04123262: Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

Recruiting
2
15
US
Tamoxifen 20 mg
H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
02/23
06/23
HORMONET, NCT03870399: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Completed
2
23
US, RoW
Tamoxifen
AC Camargo Cancer Center, H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
05/23
05/23
NCT06519097: Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Recruiting
2
212
US
Vitamin E Delta Tocotrienol, DT3, Placebo
H. Lee Moffitt Cancer Center and Research Institute, American River Nutrition, LLC, National Cancer Institute (NCI)
Neoplasm of Pancreas, IPMN, Pancreatic
07/27
07/29
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT06553885: Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Not yet recruiting
2
40
US
Enfortumab Vedotin, PADCEV
H. Lee Moffitt Cancer Center and Research Institute, Astellas Pharma Inc
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
09/29
09/29
SWOG S2104, NCT05040360: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Recruiting
2
141
US
Capecitabine, Ro 09-1978/000, Xeloda, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
03/25
03/25
ALPHAMEDIX02, NCT05153772: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Active, not recruiting
2
69
US
AlphaMedix, Pb212-octreotide analog
Radiomedix, Inc., Orano Med LLC
Neuroendocrine Tumors
10/26
10/26
NCT06378047: Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Recruiting
1
3
US
Pembrolizumab, Keytruda, Irreversible Electroporation, NanoKnife
H. Lee Moffitt Cancer Center and Research Institute, Angiodynamics, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
04/27
04/27
NCT04069299: Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Recruiting
N/A
30
US
68Ga-DOTATATE, NETspot, Positron Emission Tomography (PET) Scan
H. Lee Moffitt Cancer Center and Research Institute, Advanced Accelerator Applications
Neuroendocrine Carcinoma
05/25
05/25
Bepler, Gerold
NCI-2014-00913, NCT02178163: Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Recruiting
N/A
1020
US
cytology specimen collection procedure, cytologic sampling, laboratory biomarker analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
07/26
07/26
Chiappori, Alberto
NCT01387386: Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)

Active, not recruiting
2
95
US
Topotecan, Hycamtin®, OSI-906, TKI, Tyrosine Kinase Inhibitor, Insulin Growth Factor-1 Receptor, IGF-1R, NSC-751082
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Lung Cancer
07/14
07/14
CA209-9KN, NCT03406715: Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Terminated
2
14
US
Nivolumab, BMS-936558, Ipilimumab, Yervoy®, Dendritic Cell based p53 Vaccine, Ad.p53-DC
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, MultiVir, Inc.
Small Cell Lung Cancer, Lung Cancer, Relapsed Small Cell Lung Cancer
03/22
05/22
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
MATISSE, NCT05742607: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma
Non Small Cell Lung Cancer
06/25
09/26
BTCRC-LUN17-127, NCT03575793: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Checkmark Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Jun 2021 - Jun 2021: Initial data from trial in combination with opdivo and yervoy for recurrent small cell lung cancer at ASCO 2021
Checkmark Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
May 2021 - May 2021: Data from combination with nivolumab and ipilimumab for 2L & 3L SCLC
Checkmark From trial in combination with nivolumab and plinabulin for recurrent SCLC at ASCO 2021
More
Completed
1/2
39
US
Nivolumab, Opdivo, Plinabulin, Ipilimumab, Yervoy
Salma Sabbour, BeyondSpring Pharmaceuticals Inc., Bristol-Myers Squibb, Rutgers Cancer Institute of New Jersey
Lung Cancer, SCLC
09/23
07/24
Acclaim-2, NCT05062980: Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer

Active, not recruiting
1/2
180
US
quaratusugene ozeplasmid, Reqorsa, pembrolizumab, Keytruda, docetaxel, Taxotere, ramucirumab, Cyramza, Investigator's Treatment of Choice
Genprex, Inc.
Non Small Cell Lung Cancer
12/24
12/25
NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Terminated
1
9
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Lurbinectedin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Jazz Pharmaceuticals
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
03/23
03/23
NCT03923270: Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting
1
25
US
Durvalumab, Imfinzi, MEDI4736, Tremelimumab, Olaparib Pill, Lynparza, MK-7339, Thoracic Radiotherapy
H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
06/23
01/25
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Completed
1
49
US
NBF-006
Nitto BioPharma, Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
11/23
03/24
NCT05680922: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Recruiting
1
41
US
LB2102
Legend Biotech USA Inc
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
01/28
03/28
Daud, Adil
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
OMNIA-1, NCT05578872: A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma ().

Recruiting
1/2
130
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
09/24
12/24
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy

Active, not recruiting
1
6
US
XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104
University of California, San Francisco, Xencor, Inc.
Metastatic Melanoma, Advanced Melanoma
12/25
12/25
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Recruiting
N/A
25
US
Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection
University of California, San Francisco, Merck Sharp & Dohme LLC
Melanoma, Advanced Melanoma
08/26
08/26
Simon, George
NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Terminated
1
9
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Lurbinectedin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Jazz Pharmaceuticals
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
03/23
03/23
NCT04314089: Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Active, not recruiting
1
31
US
GT103
Edward Patz
Non-small Cell Lung Cancer
04/24
03/25
STAR, NCT04053283: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

Active, not recruiting
1
186
US
NG-641
Akamis Bio
Metastatic Cancer, Epithelial Tumor
08/24
12/24
BDTX-4933-101, NCT05786924: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Active, not recruiting
1
100
US
BDTX-4933
Black Diamond Therapeutics, Inc.
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
06/26
12/26
Pan, Edward
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
Lancet, Jeffrey E
NCT06511882: Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Recruiting
2
37
US
Azacitidine, Vidaza, Decitabine, DACOGEN, Venetoclax, Venclexta
H. Lee Moffitt Cancer Center and Research Institute, AbbVie
Acute Myeloid Leukemia
06/28
06/28
NCT06660368: BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Not yet recruiting
2
52
US
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
H. Lee Moffitt Cancer Center and Research Institute, AbbVie
Relapsed or Refractory Acute Myeloid Leukemia (AML)
11/27
11/27
MCC-20963, NCT05177211: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Active, not recruiting
2
25
US
Fedratinib Pill, Inrebic
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia, MDS
12/24
12/25
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Hourglass Jul 2019 - Sep 2019 : From P1b portion of P1b/2 trial
Completed
1/2
33
US
PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C
Prescient Therapeutics, Ltd.
Acute Leukemia
10/23
03/24
NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Recruiting
1/2
41
US
Canakinumab Injection, Ilaris, Darbepoetin Alfa, Aranesp
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals
Myelodysplastic Syndromes
12/24
10/25
NCT04620681: CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Active, not recruiting
1/2
19
US
CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy
H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
07/24
07/25
NCT03826082: PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory CD33-Positive AML or High Risk MDS

Not yet recruiting
1
56
US
PRGN-3600 T Cells
H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes, Acute Myeloid Leukemia
04/22
04/35
NCT03760523: Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
27
US
Minnelide
H. Lee Moffitt Cancer Center and Research Institute, Minneamrita Therapeutics LLC
Acute Myeloid Leukemia
10/23
10/23
NCT06327685: Avapritinib With Decitabine in Patients With SM-AHN

Recruiting
1
34
US
Avapritinib, Ayvakit, Decitabine, Dacogen, Decitabine/Cedazuridine, Inqovi
H. Lee Moffitt Cancer Center and Research Institute, Blueprint Medicines Corporation
Systemic Mastocytosis With an Associated Hematologic Neoplasm
03/27
03/27
NCT05024552: Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Recruiting
1
22
US
Gilteritinib, Xospata, Vyxeos, daunorubicin-cytarabine
H. Lee Moffitt Cancer Center and Research Institute, Jazz Pharmaceuticals
Acute Myeloid Leukemia With FLT3/ITD Mutation
11/24
11/25
NCT05015426: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Active, not recruiting
1
20
US
Gamma Delta T-Cell Infusion
H. Lee Moffitt Cancer Center and Research Institute, Florida Department of Health
Acute Myeloid Leukemia
09/25
09/26
NCT04380441: Quality of Life Model for Older Patients With AML

Active, not recruiting
N/A
206
US
H. Lee Moffitt Cancer Center and Research Institute, National Institute of Nursing Research (NINR)
AML, Adult, Acute Myeloid Leukemia
11/23
11/24
Chowdhary, Sajeel
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
ROADS, NCT04365374: Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile- (Radiation One and Done Study)

Recruiting
3
180
US
Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Carrier Tile Brachytherapy Therapy (CTBT), Stereotactic Radiation Therapy
GT Medical Technologies, Inc.
Brain Metastases
12/25
12/27
NCT03224767: Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Active, not recruiting
2
24
US
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
BRAF V600E Mutation Present, Papillary Craniopharyngioma
10/24
08/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
05/25
05/27
Homsi, Jade
NCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Hourglass Jan 2023 - Dec 2023 : Results for stage I-III MCC that has been completely removed by surgery
Active, not recruiting
3
280
US
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
12/25
12/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
12/24
07/25
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
 

Download Options